Rong Chen, PhD
- ASSISTANT PROFESSOR | Genetics and Genomic Sciences
Research Topics:
Bioinformatics, Cancer, Genetics, Genomics, Systems Biology, Transplantation
Dr. Chen's research focuses on developing databases, genome repositories, and clinical applications to interpret personal genomes for clinical diagnosis, precision medicine, predictive disease risk, and novel therapeutics.
Prior to Mount Sinai, he led the collaborative efforts at Stanford University to drive personalized medicine and clinical diagnosis on Mendelian and complex diseases using genome and exome sequencing. Dr. Chen also helped launch a startup company Personalis, which won the VA's contract for the Million Veteran Genome project.
Dr. Chen has a broad interest in translational bioinformatics and genome interpretation, and has published over 60 papers in Lancet, Cell, Nature Biotechnology, Nature Methods, PNAS, AJHG, PLoS Genetics, PLoS Computational Biology, Genome Research, Genome Biology, Genome Medicine, AJT, and Proteins. He holds numerous patents for software and databases on personalized medicine, diagnosis, and structure modeling.
p.p1 {margin: 0.0px 0.0px 0.0px 0.0px; font: 12.0px 'Helvetica Neue'}Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM], Microbiology [MIC], Neuroscience [NEU], Pharmacology and Therapeutics Discovery [PTD]Education
BS, University of Science and Technology of China
MS, Shanghai Institute of Organic Chemistry
PhD, Boston University
-
2011
ICHG Young Investigator Awards
My research focuses on translational bioinformatics and genome interpretation. We have been building hundreds of databases from mining literature and public repositories, and integrating genomic, genetic, phenotypic, clinical, and environmental data to illustrate disease mechanisms, identify diagnostics biomarkers, and drive personalized medicine. For more about informatics, please check Chen Laboratory.
To view a complete list of publications, please click here.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Chen during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Employment:
- Sema4
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.